| Autor: |
George Georges, A. Vele, Giorgio Walter Canonica, Christian Virchow, Alberto Papi, Maxim Kots, Dave Singh |
| Rok vydání: |
2020 |
| Předmět: |
|
| Zdroj: |
Airway pharmacology and treatment. |
| DOI: |
10.1183/13993003.congress-2020.2637 |
| Popis: |
Introduction: Asthma exacerbations cluster by seasons with peaks in the autumn, winter and spring. Aims and Objectives: We evaluated the effect of extra-fine beclomethasone dipropionate/formoterol fumarate/glycopyrronium bromide (BDP/FF/GB) pressurized metered dose inhaler (pMDI) on asthma exacerbation rates during the four seasons. Methods: This was a post-hoc analysis of pooled data from two phase III multinational, randomized, parallel group trial comparing a 52-week treatment with BDP/FF/GB 400/24/50 µg/d to BDP/FF 400/24 µg/d (TRIMARAN study) and BDP/FF/GB 800/24/50 µg/d to BDP/FF 800/24 µg/d (TRIGGER study) in adult patients with uncontrolled asthma on medium or high dose ICS/LABA and a history of exacerbation in the past year. Patients with persistent airflow limitation (PAL) were identified based on FEV1 ≤80% of predicted normal and FEV1/FVC ≤0.7 after 400 μg salbutamol pMDI. Asthma exacerbations were assigned to the month corresponding to the start of the event. Seasons were normalized across northern and southern hemispheres. Results: 2291 patients were considered in this analysis, of whom 1361 had PAL. The number and rate of moderate-severe exacerbations were highest in the winter followed by autumn and spring. Reductions of moderate-severe asthma exacerbation rates with BDP/FF/GB were 11% and 23% (winter), 21% and 23% (autumn), 14% and 21% (spring), and 5 and 13% (summer) in the overall and PAL populations respectively, compared to BDP/FF. Conclusions: Treatment with extra-fine BDP/FF/GB reduces seasonal peaks of asthma exacerbations in adults with asthma uncontrolled on BDP/FF, particularly in those with PAL. |
| Databáze: |
OpenAIRE |
| Externí odkaz: |
|
